![]() |
市場調查報告書
商品編碼
1486829
全球抗輻射藥物市場:洞察、競爭格局、市場預測:2030 年Anti-Radiation Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
預計2024年至2030年期間,全球抗輻射藥物市場規模將以8.79%的複合年增長率擴大。抗輻射藥物的需求主要是由於與癌症診斷程序相關的副作用數量不斷增加、輻射或核事故暴露風險急劇增加以及對核電輻射防護的日益關注所推動的。抗輻射藥物市場的整體成長。
根據 FDA 的說法,許多醫療影像設備,包括電腦斷層掃瞄 (CT)、放射線照相和傳統的乳房 X 光檢查,都使用電離輻射來產生身體影像。這些電離輻射有可能損害 DNA 並增加罹患癌症的風險。
此外,國家毒理學計劃 (NTP) 是多個美國政府機構的一部分,包括美國國立衛生研究院 (NIH)、疾病控制和預防中心 (CDC) 以及食品和藥物管理局 (FDA)。歸類為致癌物。
根據美國國家癌症研究所 (NCI) 2019 年版,15 歲之前接受過多次 CT 掃瞄的患者患白血病和腦腫瘤的風險增加。此外,有時高水平的輻射暴露可能會影響組織,導致脫髮、皮膚發紅和白內障,從而加劇了藥物抗輻射治療的需要。
因此,診斷成像過程中高電離輻射暴露及其副作用引起的安全問題預計將增加對抗輻射藥物的需求。
本報告檢視了全球抗輻射藥物市場,並提供了市場概況,包括依化合物、適應症、輻射類型、分銷管道、區域趨勢以及進入市場的公司概況劃分的趨勢。
Anti-Radiation Drugs Market By Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, And Others), Indication (Acute Radiation Syndrome, Cancer Treatment, And Others), Radiation Type (Ionizing Radiations And Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing increasing number side effects associated cancer diagnostic procedures and surge in risk of exposure to radiological or nuclear accidents around the globe during the forecast period.
The global Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030. The demand for anti-radiation drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.
Anti-Radiation Drugs Market Dynamics:
According to the FDA, most medical imaging equipment such as Computed Tomography (CT), radiography, and conventional mammography all use ionizing radiation to generate images of the body. These ionizing radiations have enough potential to damage DNA and elevate the risk of developing cancer.
In addition, the National Toxicology Program (NTP) formed from parts of several different US government agencies, including the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), has classified x- and gamma radiation as a human carcinogen.
As per the NCI (National Cancer Institute) 2019, patients who have had multiple CT scans before the age of 15 were found to have an increased risk of developing leukemia, and brain tumors. Moreover, sometimes the high levels of radiation exposure can affect tissues and cause hair loss, skin reddening, cataracts, and other problems that might aggravate the need for anti-radiation treatments in the form of drugs.
Therefore, safety concerns due to exposure to high ionizing radiations and their side effects during diagnostic imaging are expected to bolster the demand for anti-radiation pharmaceuticals.
Hence, the interplay of all the above-mentioned factors is anticipated to increase the overall market growth for anti-radiation drugs during the forecast period from 2024 - 2030.
However, the lack of disease-related expertise among healthcare professionals, and ethical and legal complications for finding adequate sample size for clinical trials and research, among others may restrict the growth of the overall market for anti-radiation drugs during the forecast period.
Anti-Radiation Drugs Market Segment Analysis:
Anti-Radiation Drugs Market by Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and others), Indication (Acute Radiation Syndrome, Cancer Treatment, and others), Radiation Type (Ionizing Radiations and Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide.
One form of radioactive material that can be used to help prevent radioactive iodine (I-131) from being absorbed by the thyroid is potassium iodide (KI), a non-radioactive form of iodine. During a nuclear accident, radioactive iodine may be released into the environment in a plume or cloud and subsequently contaminate soil, surfaces, food, and water.
The best results from KI come from taking it immediately before or right after internal radioactive iodine contamination. The amount of radioactive iodine that enters the body and how quickly it is absorbed by the body both affect how effective KI is.
KI is usually presented in scored tablets, which facilitates fractionation for pediatric dosage. The tablets have also been proven as a protective agent during wars for mass protection.
According to the European Commission (2022) in 2022, during the Ukraine war, the Government of Ukraine ordered KI pills from the European Government as a preventative safety measure to increase the level of protection around the Zaporizhzhia nuclear power plant. The potassium iodide tablets would be used in limited scenarios to avoid that inhaled or swallowed radioactive iodine is absorbed by the thyroid; to which the EU Emergency Response Coordination Centre swiftly mobilized 5.5 million potassium iodide tablets via the EU Civil Protection Mechanism for Ukraine.
Therefore, considering the advantages associated with KI in radioactive protection, it is expected to thereby contribute to the overall market growth for anti-radiation drugs during the forecast period from 2024 to 2030.
North America Is Expected To Dominate The Overall Anti-Radiation Drugs Market:
Among all the regions, North America is estimated to account for the largest share of the Anti-Radiation Drugs market in the year 2023. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, rising diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.
For instance, one of the prominent reasons for the requirement for a high number of anti-radiation drugs is the surge in the prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, 2024 data in 2024, it was estimated that approximately 2 million new cancers will be diagnosed in the United States. This ultimately would lead to more demand for anti-radiation drugs resulting from a large number of cancer diagnostic procedures. Moreover, the extensive focus on clinical research and the presence of key players in the region from the pharmaceutical domain further help in the growth of the US anti-radiation drugs treatment market.
Furthermore, in 2022, The US Department of Health and Human Services (HHS) spent USD 290 million on a drug to treat radiation sickness in the event of a nuclear emergency; buying the drug Nplate from Amgen USA Inc. as part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.
Therefore, the interplay of all the above-mentioned factors is expected to aid in the growing demand for anti-radiation drugs, thus driving the overall regional market for North America Anti-Radiation Drugs.
Anti-Radiation Drugs Market Key Players:
Some of the key market players operating in the anti-radiation drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.
Recent Developmental Activities In The Anti-Radiation Drugs Market:
Key Takeaways From The Anti-Radiation Drugs Market Report Study
Target Audience Who Can Benefit From This Anti-Radiation Drugs Market Report Study
Frequently Asked Questions For The Anti-Radiation Drugs Market:
Anti-radiation drugs are specially formulated medications that could potentially help limit or treat the health effects of certain types of radiation in a radiological or nuclear emergency.
The Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030.
The demand for Anti-Radiation Drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.
Some of the key market players operating in the Anti-Radiation Drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.
North America is expected to dominate the overall Anti-Radiation Drugs market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.